Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2006-01-09
2009-08-25
Badio, Barbara P (Department: 1612)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S180000, C552S610000
Reexamination Certificate
active
07579335
ABSTRACT:
The present invention is directed to compounds of formula (I):whereinR1represents C4-C7branched alkyl group, a bicycloalkyl group, or a C5-C6cycloalkyl which optionally may be substituted with a C1-C4alkyl group;R2represents hydrogen, a methyl group, which may be in either the α or β configuration, or a methylene group;R3and R4are the same or a different group and each independently represents hydrogen, halogen or a methyl group;represents a single or a double bond;and physiologically acceptable solvates thereof, physiologically functional derivatives thereof, pharmaceutical compositions comprising the compounds, the use of the compounds for the manufacture of medicaments particularly for the treatment of inflammatory and/or allergic conditions, processes for the preparation of the compounds, and chemical intermediates in the processes for the manufacture of the compounds.
REFERENCES:
patent: 3856828 (1974-12-01), Phillipps et al.
patent: 4996335 (1991-02-01), Bodor
patent: 5552438 (1996-09-01), Christensen, IV
patent: 6172054 (2001-01-01), Clark
patent: 6245804 (2001-06-01), Lehmann et al.
patent: 6395738 (2002-05-01), Ohshima et al.
patent: 6897224 (2005-05-01), Jaroch et al.
patent: 7288536 (2007-10-01), Biggadike et al.
patent: 7291609 (2007-11-01), Biggadike et al.
patent: 1384372 (1975-02-01), None
patent: 1514476 (1978-06-01), None
patent: 2079755 (1982-01-01), None
patent: 2137206 (1984-10-01), None
patent: 8903390 (1989-04-01), None
patent: 9313055 (1993-07-01), None
patent: 9534534 (1995-12-01), None
patent: 9741867 (1997-11-01), None
patent: 9830537 (1998-07-01), None
patent: 9854159 (1998-12-01), None
patent: 9916766 (1999-04-01), None
patent: 9932127 (1999-07-01), None
patent: 9947505 (1999-09-01), None
patent: 9962875 (1999-12-01), None
patent: 0066590 (2000-11-01), None
patent: 0104118 (2001-01-01), None
patent: 0110143 (2001-02-01), None
patent: 0116128 (2001-03-01), None
patent: 0142193 (2001-06-01), None
patent: 0200679 (2002-01-01), None
patent: 0202565 (2002-01-01), None
patent: 0226722 (2002-04-01), None
patent: 0240030 (2002-05-01), None
patent: 0250021 (2002-06-01), None
patent: 02066422 (2002-08-01), None
patent: 02070490 (2002-09-01), None
patent: 02076933 (2002-10-01), None
patent: 03008277 (2003-01-01), None
patent: 03024439 (2003-03-01), None
patent: 03042160 (2003-05-01), None
patent: 03059899 (2003-07-01), None
patent: 03061651 (2003-07-01), None
patent: 03072539 (2003-09-01), None
patent: 03082280 (2003-10-01), None
patent: 03082787 (2003-10-01), None
patent: 03082827 (2003-10-01), None
patent: 03086294 (2003-10-01), None
patent: 03091204 (2003-11-01), None
patent: 03101932 (2003-12-01), None
patent: 03104195 (2003-12-01), None
patent: 2004005229 (2004-01-01), None
patent: 2004009016 (2004-01-01), None
patent: 2004009017 (2004-01-01), None
patent: 2004016578 (2004-02-01), None
patent: 2004018429 (2004-03-01), None
patent: 2004022547 (2004-03-01), None
patent: 2004024728 (2004-03-01), None
patent: 2004026248 (2004-04-01), None
patent: 2004037768 (2004-05-01), None
patent: 2004037773 (2004-05-01), None
patent: 2004037807 (2004-05-01), None
patent: 2004039762 (2004-05-01), None
patent: 2004039766 (2004-05-01), None
patent: 2004056823 (2004-07-01), None
patent: 2004103998 (2004-07-01), None
patent: 2005005451 (2005-01-01), None
Ray et al.; “Induction of the E-selectin promoter by interleukin 1 and tumor necrosis factor alpha, and inhibition by glucocorticoids”; Biochem. J.; 1997; vol. 328; pp. 707-715.
Landells et al.; “Oral Administration of the Phosphodiesterase (PDE)4 Inhibitor, V11294A Inhibits Ex-Vivo Agonist-Induced Cell Activation” (Annu Cong Eur Resp Soc, Sep. 22, 1998); Eur. Respir. J.; 1998; vol. 12 (Suppl. 28); Abstract P2393, p. 362s.
Phillipps et al.; “Synthesis and Structure—Activity Relationships in a Series of Antiinflammatory Corticosteroid Analogues, Halomethyl Androstane -17beta-carbothioates and -17beta-carboselenoates”; J. Med. Chem.; 1994; vol. 37; pp. 3717-3729.
Rachwal et al.; “Chemistry of loteprednol etabonate and related steroids. II. Reactions at ring C and NMR structural studies of the resulting compounds”; Steroids; 1998; vol. 63, No. 4; pp. 193-201.
Austin et al.; “Mometasone furoate is a less specific glucocorticoid than fluticasone propionate”; Eur. Respir. J.; 2002; vol. 20; pp. 1386-1392.
Ueno et al.; “Synthesis and eveluation of antiinflammatory activities of a series of corticosteroid 17.alpha.-esters containing a functional group”; J. Med. Chem.; 1991; vol. 34, No. 8; pp. 2468-2473.
Fujii et al.; “Novel Phosphodiesterase 4 Inhibitor T-440 Reverses and Prevents Human Bronchial Contraction Induced by Allergen”; J. Pharmacol. Exp. Ther.; 1998; vol. 284, No. 1; pp. 162-169.
Souillac et al.; “Characterization of Delivery Systems, Differential Scanning Calorimetry”; Encyclopedia of Controlled Drug Delivery; 1999; pp. 212-227.
Vippagunta et al.; “Crystalline Solids”; Advanced Drug Delivery Reviews; 2001; vol. 48; pp. 3-26.
Druzgala et al.; “Soft Drugs—10. Blanching Activity and Receptor Binding Affinity of a New Type of Glucocorticoid: Loteprednol Etabonate”; J. Steroid Biochem. Molec. Biol.; 1991; vol. 38, No. 2; pp. 149-154.
Szelenyi et al.; “Loteprednol etabonate: a soft steroid for the treatment of allergic diseases of the airways”; Drugs of Today; 2000; vol. 36, No. 5; pp. 313-320.
Biggadike Keith
Needham Deborah
Badio Barbara P
Glaxo Group Limited
Riek James P.
LandOfFree
Androstane 17α-carbonate derivatives for use in the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Androstane 17α-carbonate derivatives for use in the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Androstane 17α-carbonate derivatives for use in the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4074713